Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Breakthrough Bleeds Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support ICD-10 Codes for Rare Bleeding Disorders
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo
Important Safety Information | Patient Site
Prescribing Information
    • Why Esperoct®
    • Pharmacology
    • Mechanism of Action
    • Prophylaxis
    • On Demand & Perioperative
    • Safety Profile
    • Dosing
    • Reconstitution & Administration
  • Cost & Coverage
    • Patient Education
    • Education for You
    • How to Order
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] logo

Indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. Esperoct® is not indicated for the treatment of von Willebrand disease.

Prescribing Information
Important Safety Information | Patient Site

Talk to us about Esperoct®.

Esperoct® has the broadest storage temperature of all EHL products1-6,a

EHL = extended half-life.

Knowing that I can take Esperoct with me on the go is a huge comfort quote

Vaughn has
hemophilia A
and uses
Esperoct®.

Knowing that I can take Esperoct with me on the go is a huge comfort quote

Vaughn has
hemophilia A
and uses
Esperoct®.

aPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.

Storage temperature icon

Patients with hemophilia A said storage flexibility is the second strongest driver when choosing a product7,b

In a clinical study, the strongest drivers of product choice were origin of FVIII (plasma-derived vs recombinant), storage flexibility (temperature), reconstitution device7,b

bStudy of 200 patients diagnosed with moderate or severe hemophilia A to gain insights on usage of factor VIII products and to assess the impact and perceived importance of product storage. Data were collected via 30-minute, face-to-face interview and via a web-based survey. A questionnaire evaluated the effect of 6 features associated with factor VIII products on the choice of the product.7

Do you treat patients who are looking for flexibility that includes . . .

Ryan smiling

Ryan is 41 years old and has severe hemophilia A. He lives in a warm climate where the average monthly temperature is 95° F.

Actor portrayal. This is a hypothetical patient story.

Offer your patients like Ryan the broadest temperature stability1-6

Before reconstitution:

Storage and temperature information graphic
Esperoct® temperature storage data from 36 to 46 degrees for up to 30 months, from 86 degrees for up to 12 months, from 104 degrees for up to 3 months

After reconstitution: use within 4 hours when stored at up to 86 °F or within 24 hours when stored in the refrigerator.1

See Prescribing Information for complete product storage information. Store reconstituted product in vial.

Learn more

Vial icon

Current treatment experience

- SHL FVIII therapy 3x/week and an ABR of 5
- Has not expressed a strong interest in changing therapies

24 clock icon

Daily life

- Active in local advocacy group
- Concerned about the long-term impact of bleeds
- Lives in an area prone to power outages and prefers to take his factor with him

ABR=annualized bleeding rate; FVIII=Factor VIII

Jackson playing video games

Jackson is 14 years old and has moderate hemophilia A. He’s motivated to adhere to treatment so he can stay active.

Actor portrayal. This is a hypothetical patient story.

Offer your patients like Jackson individualized prophylaxis dosing frequency with 1 proven starting dosec

Routine prophylaxis: 50 IU/kg every 4 days for adults and adolescents ≥12 years of age1

  • No dose adjustment needed or related PK testing is required1,8
  • This regimen may be individually adjusted to less or more frequent dosing based on bleeding episodes1
50% down icon
Learn more

Vial icon

Current treatment experience

- Prophylaxis with FVIII 2x/weekly and an ABR of 2
- Because of a joint bleed, he sometimes wears a brace

24 clock icon

Daily life

- Feels his hemophilia holds him back
- Sometimes faces bullying from peers about his hemophilia
- Parents and friends encourage him to be active

ABR=annualized bleeding rate; FVIII=Factor VIII; SHL=standard half-life

cBased on bleeding episodes. See Prescribing Information for complete dosing instructions. 
d50% fewer if previously dosed every other day, 40% fewer if previously dosed 3x/week1

Oliver on a playground

Oliver is 6 years old and was diagnosed at birth with moderate hemophilia A.

Actor portrayal. This is a hypothetical patient story.

Offer your pediatric patients like Oliver a flexible factor he can stay with1,9

Long-term trial results confirm effective prophylaxis. A lower overall median ABR in pediatric patients compared with the main phase was achieved.1,9,c,d

Results in previously treated children (aged 0-11 years) up to 5.4 years

0.8 statistic icon
43% down icon
Learn more

Vial icon

Current treatment experience

- Has switched to EHL FVIII therapies twice due to breakthrough bleeds
- ABR of 3

24 clock icon

Daily life

- Spends time at his grandparents’ but finds it hard to sit still
- His parents are concerned about the need to switch FVIII therapy
- Oliver’s mother is active with a caregiver group and at a local HTC

ABR=annualized bleeding rate; EHL=extended half-life; FVIII=Factor VIII; HTC=hemophilia treatment center; PK=pharmacokinetic; SHL=standard half-life

cIn a phase 3, multinational, open-label, single-arm, nonrandomized, noncontrolled trial of 68 previously treated male patients aged <12 years with severe congenital hemophilia A, comprising main phase and and extension phase.1,9

dMedian ABR shown is from the main and extension phases of previously treated children with severe hemophilia A who took Esperoct® 60 IU/kg (50-75 IU/kg) twice weekly for a median of 4.9 years.9

e43% fewer if previously dosed every other day, 33% fewer if previously dosed 3x/week1

Erica smiling

Erica is a 36-year-old event planner who has had symptoms since childhood but wasn’t diagnosed with mild hemophilia until she was 33.

Actor portrayal. This is a hypothetical patient story.

Offer your patients like Erica flexible factor with bleed protection for all age groups1,c  

Achieve high trough levels for a broad range of patients
Trough levels stabilized in the range of mild/moderate hemophilia for a majority of the time in adults and adolescents1

Trough levels over time graphic
Trough levels over time graphic
Learn more

Vial icon

Current treatment experience

- Uses hormonal contraception to control heavy menstruation
- Hemorrhaged after delivery of first child
- Has severe bleeding phenotype and joint pain despite mild diagnosis and use of FVIII on demand

24 clock icon

Daily life

- Normalized low energy and painful bruising
- Endures symptoms to prioritize her son’s hemophilia treatment
- Travels for work and prefers a treatment she can take along easily

ABR=annualized bleeding rate; FVIII=Factor VIII; PK=pharmacokinetic; SHL=standard half-life

cPrior to reconstitution, Esperoct® can be stored from 36 °F to 46 °F for up to 30 months, at room temperature up to 86 °F for up to 12 months, or up to 104 °F for up to 3 months.1 See Prescribing Information for complete product storage information.

dIn a phase 3, open-label study, safety, efficacy, and pharmacokinetics (PK) of Esperoct® were evaluated in previously treated patients (PTPs) aged ≥12 years with severe hemophilia A. 175 PTPs received routine prophylaxis (50 IU/kg Q4D) for 76 weeks. Steady-state peak and trough levels were recorded from 143 adults and 23 adolescents. Mean trough levels for adolescents (aged 12 to <18 years) were 2.7 IU/dL.1

eSteady-state FVIII activity profiles were estimated in 143 patients using a one-compartment model with first-order elimination with PK parameters of clearance and volume of distribution.1

fPost hoc analyses were performed on data from the pathfinder2 trial of patients aged ≥12 years with severe hemophilia A who received prophylaxis Q4D. Exploratory descriptive analyses of the data were used to evaluate long-term annual bleed rates and mean factor VIII trough levels which were assessed over time in 53 patients aged ≥12 years with severe hemophilia who received ≥6 years of prophylaxis, every 4 days. Limitations of the analyses include the lack of baseline joint status data, which is clinically relevant for phenotypic assessment prior to treatment initiation. The absence limits the ability to draw conclusions regarding improvement in joint status over time. Several trough-level data were excluded if it was believed that they were elevated due to dosing to treat a recent bleed.10

Help your patients navigate coverage

Mother and child smiling

NovoCare® offers cost savings and support programs for your eligible patients with bleeding disorders.

Find support

Order Esperoct® for your patients

Esperoct® package

Order Esperoct® by phone, through an authorized trading partner, or by contacting your local Novo Nordisk representative.

See how to order

Selected Important Safety Information for Esperoct®

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment

Indications and Usage

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes

  • Esperoct® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
  • Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
  • Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®

Adverse Reactions

  • The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.

Please click here for Esperoct® Prescribing Information.

References:
  1. Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk, Inc.
  2. Adynovate® [package insert]. Lexington, MA: Baxalta US Inc; 2023.
  3. Afstyla® [package insert]. Kankakee, IL: CSL Behring LLC; 2023.
  4. Altuviiio® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.      
  5. Eloctate® [package insert]. Waltham, MA: Bioverativ Therapeutics Inc; 2023.      
  6. Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
  7. Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence. 2018;12:431-441.
  8. Giangrande P, Abdul Karim F, Nemes L, et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost. 2020;18(suppl 10):5-14.
  9. Saulyte Trakymiené S, Economou M, Kenet G, Landorph A, Shen C, Kearney S. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: final results from pathfinder5. Thromb Haemost. 2020;18(suppl 10):15-25.
  10. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdry P. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2022;28(1):27-35.
  11. Meunier S, Alamelu J, Ehrenforth S, et al. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A. Thromb Haemost. 2017;117(9):1705-1713.
Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore rare renal disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Breakthrough Bleeds
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support
      ICD-10 Codes for Rare Bleeding Disorders

Esperoct® is a registered trademark of Novo Nordisk Health Care AG.
NovoCare® is a registered trademark of Novo Nordisk A/S.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2024 Novo Nordisk All rights reserved. US24ESP00008 August 2024

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials